ISSN: 0975-8585

Research Journal of Pharmaceutical, Biological and Chemical Sciences

Epigenetic Regulation in Diabetes: A Focus on DNA Methylation and Histone Modifications.

Aryan Gupta[1], Charu Yadav[1], Khushi Mehra[1], Saumya Bala Verma[1], Runjhun Mathur[2], Mohini Vats[1]*, and Abhimanyu Kumar Jha[3]*.

[1]Department Of Biotechnology, School of Engineering and Technology, Sharda University, Greater Noida, Uttar Pradesh, 201310, India.
[2]Dr. A.P.J Abdul Kalam Technical University, Lucknow. Uttar Pradesh, India.
[3]Department of Biotechnology, School of Biosciences and Technology, Galgotias University, Greater Noida, Uttar Pradesh, Noida.

ABSTRACT

Diabetes Mellitus (DM) represents a significant worldwide health issue, affecting over 400 million individuals worldwide. This condition is primarily characterized by Decreased insulin secretion, impaired pancreatic β-cell function, and resistance to insulin. Recent studies have highlighted the role of epigenetic mechanisms, including DNA methylation, histone modifications, and non-coding RNAs, in the pathogenesis of diabetes. These epigenetic alterations influence Regulation of gene activity without altering the DNA sequence, thereby contributing to the development and progression of Diabetes along with its related complications. This paper reviews the current understanding of epigenomic changes associated with diabetes, emphasizing their implications for disease management and potential therapeutic targets.
Keywords: diabetes, DNA methylation, histone.

https://doi.org/10.33887/rjpbcs/2025.16.1.16

Corresponding author

ISSN: 0975-8585

INTRODUCTION

Diabetes Mellitus (DM) is a significant global medical issue, impacting over 400 million individuals globally. The primary factors contributing to this condition include reduced insulin production, malfunctioning β cells in the pancreas, and insulin resistance due to inadequate insulin use [1]. Non-communicable diseases (NCDs) were responsible for 74% of global deaths in 2019, with diabetes ranking among the top ten causes and contributing to 1.6 million deaths, as reported by the World Health Organization (WHO). Projections estimate that by 2035, the global prevalence of diabetes could rise to 592 million individuals [2]. The International Diabetes Federation reports that probably 8.8% of adults globally are living with diabetes, with a higher prevalence in men (9.6%) compared to women (9.0%). Currently, there are 463 million individuals with diabetes, and an additional 374 million are estimated to have impaired glucose tolerance (IGT), a precursor to diabetes. By 2045, it is anticipated that around 700 million citizens will have diabetes & 548 million will have IGT, marking a 51% increase from 2019 [3]. In India, the proportion of individuals with diabetes rose from 7.1% in 2009 to 8.9% in 2019, with the country housing 77 million diabetics, making it the second highest globally after China. Furthermore, it is estimated that 43.9 million people in India remain undiagnosed, which constitutes about 57% of the total diabetes cases in the nation [4].

In terms of the pervasiveness of polygenic diseases, it was discovered that there was a 14.7% prevalence of rapid dysglycemia in 38.95% of the Venezuelan sample, 7% in cases of prediabetes. Whereas, the WHO study indicates that the country of South America has a calculated 8.8% prevalence of diabetes mellitus among associates in nursing. There is a strong possibility that the occurrence of diabetes-related problems will rise significantly because of the rise in body fat percentage [5].

Epigenetic factors have a profound effect on target organs, including improper growth promotion and incorrect expression of pro-fibrotic and pro-apoptotic genes. However, it is clarified that there are no modifications to the deoxyribonucleic acid (DNA) sequence; rather, it is a heritable shift in gene expression. Histone modifications, non-coding microRNAs (miRNA), and cytosine methylation are all considered as epigenetic factors. Each of these factors either individually or in combination affect the level of gene expression. Environmental aspects contributing to the inception of (T2D) include an inadequate in Low birth weight, obesity, advanced age, and the uterine environment. In vertebrates, DNA methylation primarily targets cytosine, leading to the silencing of transcription [6].

Types of Diabetes Mellitus

Type 1 Diabetes Mellitus

Certain genetic loci, particularly The HLA region located on chromosome 6p21, the PTPN22 gene on chromosome 1p13, and the INS gene on chromosome 11p15 are closely linked to genetic predisposition for Type 1 diabetes mellitus. Recent statistics indicate that the Occurrence of Type 1 diabetes among Young children below the age of 15 is rising at a rate of 3–5% each year, resulting in approximately 65,000 new cases annually. This upward trend has been correlated with various environmental factors, including deficiencies in vitamin D, consumption of milk proteins, exposure to retroviruses, and environmental pollutants, all of which may facilitate the autoimmune response that triggers to the destruction of insulin-producing β-cells [6].

Moreover, studies have suggested that the Genetic correlation predisposition and recognizing environmental influences is vital in the progression of Type 1 diabetes. For instance, research has shown that early exposure to certain dietary proteins may influence the immune system's development and its subsequent response to pancreatic β-cells [7]. Additionally, the involvement of gut microbiota in affecting immune responses has gained attention, with evidence suggesting that alterations in gut microbial composition may impact the risk of developing autoimmune conditions, including Type 1 diabetes [8].

Type 2 Diabetes Mellitus

Type 2 diabetes is a complicated metabolic condition distinguished by prolonged hyperglycemia. It arises from the interaction of genetic factors and environmental influences, including inadequate diet, sedentary lifestyle, advancing age, and obesity. Chronic hyperglycemia deregulates immune responses, leading to elevated cytokine levels and systemic inflammation [9]. Gene expression modifications, including

DNA methylation in genes like INS, PDX1, PPARGC1A, and GLP1R, are linked to Deficient insulin secretion and hyperglycemia-induced damage in pancreatic microstructures [10].



Gestational Diabetes Mellitus

Gestational diabetes mellitus (GDM) is a pregnancy-associated Dysmetabolism marked by hyperglycemia. It is associated with challenges such as premature birth, hypertension, and an elevated risk of chronic metabolic conditions for both the mother and offspring. Epigenomic processes, particularly modifications in the methylation patterns of DNA within specific genes like HOOK2, RDH12, and TNFRSF1B, have been closely linked to gestational diabetes mellitus (GDM). Studies suggest that exposure to GDM in utero can lead to enduring epigenetic modifications, which may heighten the possibility of obesity & metabolic Disorders in descendants as they grow older [11].

Risk Factors of Diabetes Mellitus

Autoimmune Factors in Type 1 Diabetes

Type 1 diabetes typically presents during pre- adulthood and Occurs due to the immune system's attack on insulin-secreting β-cells. Latent autoimmune diabetes in adults (LADA), a closely related subtype, exhibits Traits of both Type 1 and Type 2 diabetes, with a gradual onset and slower progression to insulin dependence in adult individuals. LADA patients exhibit immunological, phenotypic, and genetic heterogeneity and require personalized treatment strategies to preserve β-cell function and manage glucometabolic regulation [12].

Vitamin D Deficiency

Vitamin D act as a fundamental involvement in preventing insulin secretion and β-cell function. Deficiency in vitamin D leads to hypermethylation of diabetes-related genes and impairs calcium and reactive oxygen species signaling, exacerbating Insulin unresponsiveness and β-cell impairment Supplementing vitamin D helps maintain normal epigenomic patterns, reducing the elevated risk of diabetes onset [13, 14].

Complications of Diabetes Mellitus

Diabetic Retinopathy (DR)

Diabetic retinopathy (DR) is a Primary cause of vision loss and blindness, which is typified by abnormalities in the retinal vascular system. Retinal microvascular damage is a result of metabolic pathways brought on by hyperglycemia, including the polyol pathway and protein kinase C activation. According to Wang et al. (2018) [15], glycemic control, the length of diabetes, and genetic predispositions all affect the progression of DR via non-proliferative and proliferative stages.

Diabetic Nephropathy (DN)

Diabetic nephropathy is acknowledged as a critical microvascular complication of diabetes and a frequent cause of end-stage renal disease (ESRD). It is stated by hyperfiltration, the existence of albumin in urine (albuminuria), and a gradual decline in renal function. Additionally, Cardiovascular disease is a

primary cause of mortality among patients with diabetic nephropathy (DN), highlighting the importance of implementing metabolic and hemodynamic interventions to slow the development of the disorder [16].

Diabetic Neuropathy (DN)

Diabetic neuropathy (DN) affects peripheral, autonomic, and central nervous systems, with distal symmetrical sensorimotor polyneuropathy being the most common manifestation. Symptoms include chronic pain, poor sleep, and increased risk of extremity amputation. Management strategies focus on glycemic control, quality-of-life improvement, and pain management using medications like gabapentin and duloxetine [17].

Epigenetic Mechanisms Associated with Diabetes Mellitus

Epigenetics is outlined as reversible changes in gene expression, with no alteration in gene sequence [18]. Epigenetics encompasses the inheritance of traits that are not directly embedded in the DNA sequence but influence gene function [19]. DNA methylation, which involves adding methyl groups to DNA's cytosine bases, is a crucial process of epigenetic regulation involving non-coding RNA. In order to influence gene expression, this process usually entails Cytosine methylation within CpG sites, which are commonly present in the Regulatory regions upstream of genes. Proteins Associated in chromatin remodeling and transcription factors can be impacted by methylation.



Figure 1: Epigenetic Mechanisms in Diabetes Mellitus

DNA Methylation

Mammals can transmit epigenetic information through various mechanisms, one of which is mitotically stable DNA methylation [20]. In recent decades, scientists/researchers have uncovered significant insights into the process of DNA methylation, including its occurrence, mechanisms, and biological implications. This epigenetic modification plays a pivotal role in key processes like as X-chromosome inactivation, embryonic development, and maintaining chromosome stability. Given the critical functions of DNA methylation, it is unsurprising that errors in this process are associated with numerous human diseases [21].

DNA methylation entails the attachment of Methyl groups attached to cytosine residues within CpG dinucleotides, playing a significant influence on gene expression regulation. Recent research, however, indicates that CpH methylation (with H denoting C, A, or T) may occur more frequently than previously understood [22]. Multiple genes have been reported to be aberrantly silenced by hypermethylation in acute

leukemia [23]. Epigenetic alterations specific to tumors have been identified in serum DNA across various cancer types [24]. The hypermethylation of the LATS2 promoter serves as a significant epigenetic mechanism for silencing gene expression, contributing to cancer development.

After a thorough examination of case-control cohorts, Toperoff et al. discovered a particular DNA methylation pattern linked to type 2 diabetes mellitus. The potential role of DNA methylation as an early biomarker for determining susceptibility to T2DM is highlighted by this pattern, which appears before the onset of clinical symptoms and has a considerable effect on the risk of disease. Using genome-scale screening across 1,169 patients and controls, this study identified many differentially methylated areas that have been previously connected to type 2 diabetes through genetic research. Epigenetic changes vary across populations due to the influence of dietary habits, environmental exposures, and lifestyle factors [25].

A detailed investigation of specific loci highlighted significant hypomethylation at the initial intron of the FTO gene among T2DM patients compared to controls [26].

DNA methylation generally connects with gene regulation, where hypomethylation is linked to gene activation, while hypermethylation is associated with gene silencing. Studies also demonstrate a connection between diabetes and aberrant DNA methylation patterns. Environmental factors can influence DNA methylation, which can be inherited by daughter cells and offspring. Enzymes capable of demethylating DNA can also reverse methylation changes [27].

In diabetes, hyperglycemia is associated with both global and gene-specific changes in DNA methylation, which may affect genes related to endothelial function and vascular regulation [28]. For instance, increased methylation of the promoter for endothelial nitric oxide synthase, essential for vascular dilation, reduces its expression and activity. Conversely, hypomethylation of the vascular endothelial growth factor (VEGF) promoter may enhance its expression, promoting abnormal angiogenesis and vascular leakage. Epigenetic modifications play a crucial role in regulating the level and timing of gene expression in response to both internal and external stimuli. Furthermore, increasing evidence highlights the intricate interplay between epigenetics and metabolic processes [29]. DNA methylation influences gene expression related to glucose metabolism, insulin signaling, and β-cell functionality [30]. Studies in both T2DM patients and animal models reveal abnormal methylation patterns, implicating these changes in T2DM pathogenesis [31]. Insulin production from pancreatic β-cells and peripheral tissue insulin sensitivity are both strongly impacted by methylation. Elevated DNA methylation in the PPARGC1A promoter was found in pancreatic islets from donors with type 2 diabetes mellitus (T2DM) by [32]. This was linked to decreased gene expression and poor insulin secretion. Further emphasizing the significance of methylation in diabetes-related metabolic dysfunction, Barres and colleagues also found that the skeletal muscle of individuals with type 2 diabetes exhibits distinct methylation patterns at the PPARGC1A gene Relative to those with normal glucose tolerance.

Non-Coding RNA

Recent studies have shown that a significant part of the genome is transcribed into RNA, most of which does not code for proteins and is categorized as non-coding RNA (ncRNA). These ncRNAs are sorted into multiple types built on their size and function, includes siRNAs, miRNAs, lncRNAs, and circRNAs. Long non-coding RNAs, in specific, have drawn significant attention for their involvement in a range of pathological and physiological processes [33].

Long non-coding RNAs, including the X-inactive specific transcript engaged in X-chromosome inactivation in Eutherian mammals, were discovered almost 30 years ago. Distinguished as molecules of RNA longer than 200 nucleotides without the ability to encode proteins, lncRNAs are transcribed by RNA polymerase III or II. These transcriptions may sustain splicing and occasionally consist of a single exon. Initially regarded as genomic "dark matter," lncRNAs are now acknowledged as Critical modulators of gene expression and cellular processes [34].

LncRNAs regulate gene expression by employing multiple distinct mechanisms, functioning as signaling molecules, decoys for transcription factors, guides for targeting proteins to specific genomic loci, or scaffolds facilitating the assembly of molecular complexes. Their classification is based on their genomic orientation and position relative to neighboring genes, including categories such as sense/antisense,

divergent/convergent, and intronic/intergenic [34]. These molecules are vital for embryonic development and have been implicated in various cancers and neurodegenerative diseases.

Investigations into lncRNAs have also highlighted their involvement in aging and metabolic disorders. Quantitative analysis of their expression often employs SYBR Green-based qPCR, utilizing gene-specific primers and normalization against housekeeping genes such as beta-actin or 18S rRNA [35]. Gene silencing using siRNA holds immense promise against viral infection, indicating that targeted modulation of gene expression can be a powerful tool in managing diseases, which parallels the potential of epigenetic modifications in regulating gene expression in conditions like diabetes [36].

The metastasis-associated lung adenocarcinoma transcript 1 is a significant lncRNA associated with podocyte apoptosis under hyperglycemic conditions. MALAT1 plays a key role in a regulatory feedback loop involving β-catenin and serine/arginine splicing factor 1. Through the modulation of this pathway, MALAT1 contributes to the mitigation of podocyte damage, highlighting its potential involvement in the development of diabetic complications [33].

Table 1: Types of Non-coding RNAs (ncRNAs).

ncRNAs	Length	Characteristics
lncRNAs	>200 nucleotides	Contains 5′ end cap and a 3′ end poly(A) tail; regulates at transcriptional and posttranscriptional levels.
miRNA	17-25 nucleotides	Contains 5′ end cap and a 3′ end poly(A) tail.

Histone Modifications

Histone proteins are subject to various post-translational modifications, primarily taking place on their N-terminal tails, which are essential for regulating chromatin organization and gene activity. These alterations, such as methylation, phosphorylation, acetylation, and ubiquitination, differ in their extent and specific residue targets. The combined effects of these modifications dynamically control chromatin accessibility and transcriptional activity, thereby affecting the Regulation of gene activity in reaction to cellular and environmental cues.

These alterations are integral to chromatin remodeling, impacting the condensation state of chromatin and facilitating precise detection of such modifications. The combination, pattern, and specific location of these modifications, such as within the promoter region, CpG islands, or gene body, collectively regulate gene expression levels [6].

Histone Methylation

Histone methylation, a common type of histone modification, is the incorporation of groups of methyl groups to Particular categories lysine or arginine residues on histone protein molecules. Lysine residues can be mono-, di-, or tri-methylated, however arginine residues can be methylated either symmetrically or asymmetrically. Histone methyltransferases (HMTs) catalyze this process by transferring methyl groups from S-adenosylmethionine to the desired residue. In particular, HMTs affect not just chromatin-bound histones, but also loose histones and non-histone proteins.

In the context of metabolic disorders such as T2DM, histone modifications have been investigated for their roles in insulin regulation. For example, a global proteome analysis in mice fed a high-fat diet identified 15 histone modifications with altered prevalence. In T2DM patients, there was a noted reduction in methylation and an elevated in the expression of genes like CDKN1A and PDE7B, which negatively impacted glucose-stimulated insulin release. Additionally, elevated levels of H3K4me3 at the Fxyd3 gene in mice were found to adversely affect glucose responsiveness in insulin-secreting cells.

Further insights were gained from DNA methylation analysis of genes such as INS, PPARGC1A, PDX1 and GLP1R in pancreatic islets from T2DM donors. Studies also explored histone modifications in

monocytes cultured under different glucose conditions and assessed chromatin accessibility using ATAC-seq, primarily in non-diabetic samples [37].

Histone Acetylation and Deacetylation

Histone acetylation, a crucial post-translational modification, is continuously controlled by histone acetyltransferases and histone deacetylases. These enzymes modulate histone acetylation levels, which significantly impacts chromatin structure and gene expression. This process regulates gene activity by modulating chromatin structure. Acetylation generally promotes gene transcription, while deacetylation leads to gene silencing. Histone acetylation has been implicated in inflammation-related gene expression and autoimmune disorders. For instance, histone H3 lysine 9 acetylation, associated with transcriptional activation, is significantly elevated near susceptibility gene promoters in Type 1 diabetes (T1DM) monocytes. However, genome-wide acetylation profiling of histone H3 in T1DM immune cells remains limited. A study on CD4+ T cells from GADA-positive T1DM patients compared histone H3 acetylation with healthy controls to identify potential links to T1DM pathogenesis. Histone deacetylases (HDACs) remove acetyl groups from ε-N-acetyl-lysine residues, resulting in a more compact binding of histones to DNA. These enzymes play a vital role in regulating DNA interactions and suppressing gene expression by modifying chromatin structure. HDACs are classified into five groups based on their homology to yeast enzymes. Class I consists of HDAC1, HDAC3, HDAC2, and HDAC8; Class IIa includes HDAC4, HDAC7, HDAC5, and HDAC9; while Class IIb includes HDAC10and HDAC6. Interestingly, HDAC4 exhibits approximately 50% amino acid sequence identity with an HDAC-related protein that functions as a transcriptional repressor [38].

Histone Phosphorylation

Phosphorylation of histones is another critical modification with diverse biological implications. For example, nephrin, a key component of podocyte membranes, activates phosphotyrosine signaling pathways to protect podocytes from apoptosis. In diabetic conditions, elevated glucose levels increase SH2 domain-containing phosphatase 1 expression, reducing nephrin phosphorylation and promoting podocyte apoptosis. Similarly, diabetic nephropathy is associated with increased SHP-1 expression in diabetic mice. ROS production, driven by hyperglycemia and phosphorylation of components of nicotinamide adenine dinucleotide phosphate oxidase (NOX), contributes to oxidative stress, leading to kidney damage [39].

Epigenetic Therapy

Recent research indicates that the prevalence of diabetes mellitus, a Prolonged metabolic disease linked to a number of genetic and environmental influences, has increased globally. The rise in health complications, including diabetes-related retinopathy, cardiovascular issues nephropathy, neuropathy such as hypertension, stroke, and atherosclerosis, has become a significant concern [40]. Type 1 diabetes is an autoimmune disorder marked by impaired insulin production and pancreatic β-cell apoptosis, while T2D is characterized by impaired insulin action. Epigenetic factors play a critical role in affecting target organs, leading to abnormal growth promotion, including dysregulated cell transcription and the inappropriate expression of pro-fibrotic and pro-apoptotic genes [6].

Although there is not a clear definition for epigenetic modification, diabetes mellitus is linked to epigenetic factors. However, it can also be defined as a genetic variation in a gene's expression that does not include alteration to the deoxyribonucleic acid sequence [6]. These changes can be inherited by an organism's offspring. Histone modifications, non-coding microRNAs (miRNA), and cytosine methylation are all considered epigenetic factors. Either separately or in combination, these variables affect the degree of gene expression. Recent researches shows that, Low birth weight, obesity, advanced age, and an unfavorable in utero environment are among the environmental variables that lead to the progression of type II diabetes [40] In vertebrates, Cytosine acts as a target for DNA methylation which results in transcriptional silence. (Singh et al., 2020) [6]. An important molecular target for cancer therapy is the reactivation of tumor suppressor genes (TSGs) that have been silenced through promoter methylation [41].

Epigenetic therapy in diabetes involves targeting the epigenetic modifications that regulate gene expression. This approach aims to reverse abnormal epigenetic changes associated with diabetes such as altered DNA methylation patterns or histone alterations, which can contribute to the development and progression of the disease [6].

These therapies refers to the use drugs or other inventions to modify the Gene transcription by targeting the chemical modifications of DNA and histone proteins, rather than altering the genetic code itself [6].

There are some therapeutic targets in epigenetic therapy by which we can cure diabetes, epigenetic changes responsible for DM type 1 are histone modifications, DNA Methylation , miRNA dysregulation and there are some Histone alterations and DNA methylation are epigenetic alterations that cause type 2 diabetes. Other epigenetic molecular therapeutic targets include protein tyrosine phosphatase 1B, sirtuin 1, DNA methyltransferase, and HDACs [6].

Epigenetic Changes Responsible For Diabetes Mellitus

The autoimmune disease known as T1DM is brought on by a number of interrelated variables, including epigenetic, genetic, and environmental influences. Globally, the prevalence of T1D in children under the age of 15 is rising quickly, ranging from about 3 to 5% annually. WHO and other organizations studied that reported cases are approximately ~65000/year in teenagers, Studies also show that the incidence of T1D is higher in twins than in siblings. Environmental pollution, vitamin D exposure, milk protein consumption, and retrovirus infection are some of the environmental variables that contribute to T1D, its approximately ~ 7% chances in siblings but in twins it's about ~12-67.7% which is 0.4% of total population of world Actually, Type 1 diabetes is primarily a heritable condition, frequently observed in siblings, particularly among 15-year-olds, with the highest concordance rates seen in monozygotic twins with autoimmune susceptibility [6]. These elements provide compelling evidence of the intricate interplay between genetic and environmental variables and explain the epigenetic changes in gene expression. Histone deacetylation, DNA hypermethylation and miRNA dysregulation were the primary epigenetic modifications in the changed gene; these factors affect insulin production and the elevated risk of Type 1 diabetes [40].

Epigenetic Molecular Drug Targets

Histone and DNA alterations are the primary components of epigenetic modification, which results in phenotypic changes. These events are the main source of entertainment in this section. When it comes to genetic and environmental stress, epigenetic modifications can go either way; once the stress is removed, they return to their initial state. Recent research has demonstrated that histone modification mostly contributes to CpG island methylation, which is linked to a number of epigenetic modifications and controls. This relationship creates a new framework in which some genes, which are essentially used as on/off switches for certain cellular components, are dominated by an epigenetic code [6].

Some Epigenetic Molecular Drug Targets

Histone Deacetylases (HDACs)

HDAC inhibitors are being explored as potential treatments for diabetes. By inhibiting these enzymes, the acetylation of histones is increased, which can enhance the demonstration of genes involved in insulin signalling and β-cell function, leading to improved insulin sensitivity and better glycemic control.

Histone Acetyltransferases (HATs)

Targeting Histone acetyltransferases (HATs), which attach acetyl groups to histones, can induce a more relaxed chromatin structure, thereby promoting gene transcription. Boosting HAT activity may support the activation of genes that contribute to glucose metabolism.

DNA Methyltransferases (DNMTs)

DNMTs are responsible for adding methyl groups to DNA, leading to gene silencing. Inhibiting DNMTs could reverse abnormal gene silencing associated with diabetes, particularly in genes critical for insulin production and secretion, thereby restoring normal pancreatic function.

Non-coding RNAs

Non-coding RNAs, especially microRNAs, play a significant role in regulating gene expression. Modulating the activity of specific microRNAs could help restore normal gene expression patterns disrupted in diabetic conditions, potentially improving metabolic outcomes.

Epidrugs

Epidrugs are small molecules designed to target specific epigenetic modifications. These drugs can reverse the epigenetic changes that contribute to diabetes and its complications, offering a novel approach to treatment.

Sirtuin 1 (SIRT1)

SIRT1 is a NAD+-dependent deacetylase that plays a critical function in controlling metabolic activities, including insulin sensitivity and inflammation. It has been shown to enhance insulin signalling and maintain integrity β-cells from oxidative stress. Targeting SIRT1 with activators could improve insulin sensitivity and reduce inflammation in diabetic patients.

Protein Tyrosine Phosphatase 1B (PTP1B)

PTP1B is a Inhibitor of insulin signaling Inhibition of PTP1B can enhance insulin receptor signaling, leading to improved glucose homeostasis. This makes PTP1B a promising target for drug development aimed at increasing insulin sensitivity in type 2 diabetes.

Peroxisome Proliferator-Activated Receptors (PPARs)

PPARs, particularly PPAR-γ, are nuclear receptors that regulate glucose and lipid metabolism. Agonists of PPAR-γ, such as thiazolidinediones, are already used in clinical practice to improve insulin sensitivity. Targeting PPARs can help manage diabetes by enhancing glucose uptake and reducing insulin resistance.

AMP-Activated Protein Kinase (AMPK)

AMPK is a key energy sensor in cells that regulates glucose and lipid metabolism. Activating AMPK can improve insulin sensitivity and promote glucose uptake in muscle and adipose tissues. AMPK activators are being explored as potential therapeutic agents for diabetes management.

Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists

GLP-1 is an incretin hormone that stimulates insulin secretion after meals and suppresses glucagon release. GLP-1 receptor agonists are used to improve glycemic control in type 2 diabetes by promoting insulin secretion and reducing appetite.

CONCLUSION

The complex interaction between genetic susceptibility and environmental influences highlights the intricacy of diabetes mellitus. Epigenetic modifications, such as DNA hypermethylation and histone deacetylation, play an essential role in controlling gene expression associated with insulin production and glucose metabolism. Understanding these epigenetic mechanisms offers valuable insights into the pathophysiology of diabetes and highlights potential molecular targets for therapeutic intervention. As the global incidence of diabetes continues to increase, further research into epigenetic factors will be essential for developing effective strategies for prevention and treatment, ultimately enhancing patient outcomes and overall well-being.

REFERENCES

[1] Padhi S, Nayak AK, Behera A. Type II diabetes mellitus: a review on recent drug-based therapeutics. Biomedicine & Pharmacotherapy 2020; 131: 110708.

[2] Tao Z, Shi A, Zhao J. Epidemiological Perspectives of Diabetes. Cell Biochem Biophys 2015; 73(1): 181-5. doi: 10.1007/s12013-015-0598-4.
[3] International Diabetes Federation. IDF Diabetes Atlas 9th ed. Brussels, Belgium: International Diabetes Federation, 2019.
[4] Pradeepa R, Mohan V. Epidemiology of type 2 diabetes in India. Indian J Ophthalmol 2021; 69(11): 2932-2938. doi: 10.4103/ijo.IJO_1627_21.
[5] Kumar R, Saha P, Kumar Y, Sahana S, Dubey A, Prakash O. A Review on Diabetes Mellitus: Type1 & Type2. World J Pharm Pharm Sci 2020; 9(10): 838-850.
[6] Singh R, Chandel S, Dey D, Ghosh A, Roy S, Ravichandiran V, Ghosh D. Epigenetic modification and therapeutic targets of diabetes mellitus. Biosci Rep 2020; 40(9): BSR20202160.
[7] Ludvigsson J, et al. Dietary factors and the risk of type 1 diabetes. Diabetes Care 2018; 41(4): 763-770. doi: 10.2337/dc17-1740.
[8] Brown A, et al. The gut microbiome and type 1 diabetes: A review. Diabetes Res Clin Pract 2019; 151: 1-10. doi:10.1016/j.diabres.2019.01.001.
[9] Naidoo V, Naidoo M, Ghai M. Cell-and tissue-specific epigenetic changes associated with chronic inflammation in insulin resistance and type 2 diabetes mellitus. Scand J Immunol 2018; 88(6): e12723.
[10] Cardenas A, Gagnè-Quellet V, Allard C, et al. Placental DNA methylation adaptation to maternal glycemic response in pregnancy. Diabetes 2018; 67: 1673–83. doi: 10.2337/db18-0123.
[11] Ling C, Rönn T. Epigenetics in human obesity and type 2 diabetes. Cell Metab 2019; 29(5): 1028-1044.
[12] Pozzilli P, Pieralice S. Latent autoimmune diabetes in adults: current status and new horizons. Endocrinol Metab 2018; 33(2): 147-159.
[13] Berridge MJ. Vitamin D deficiency and diabetes. Biochem J 2017; 474(8): 1321-1332.
[14] Lips P, Eekhoff M, van Schoor N, et al. Vitamin D and type 2 diabetes. J Steroid Biochem Mol Biol 2017; 173: 280-285.
[15] Wang Y, Hou C, Wisler J, et al. Elevated histone H3 acetylation is associated with genes involved in T lymphocyte activation and glutamate decarboxylase antibody production in patients with type 1 diabetes. J Diabetes Investig 2019; 10(1): 51-61.
[16] Sagoo MK, Gnudi L. Diabetic nephropathy: an overview. Diabetic Nephropathy: Methods and Protocols 2020; 3-7.
[17] Bruschi LKM, da Rocha DA, Gesteira Filho EL, et al. Diabetes mellitus and diabetic peripheral neuropathy. Open J Endocr Metab Dis 2017; 7(1): 12-21.
[18] Mathur R, Jha AK. Reversal of hypermethylation and reactivation of tumor suppressor genes due to natural compounds in breast cancer cells. Google Scholar 2020.
[19] Ashe A, Colot V, Oldroyd BP. How does epigenetics influence the course of evolution? Philos Trans R Soc B 2021; 376(1826): 20200111.
[20] Rakyan VK, Down TA, Balding DJ, Beck S. Epigenome-wide association studies for common human diseases. Nat Rev Genet 2011; 12(8): 529-41. doi: 10.1038/nrg3000.
[21] Phillips T. The role of methylation in gene expression. Nature Education 2008; 1(1): 116.
[22] Ramsahoye BH, et al. Non-CpG methylation is prevalent in embryonic stem cells and may be mediated by DNA methyltransferase 3a. Proc Natl Acad Sci U S A 2000; 97: 5237–5242.
[23] Nikbakht M, Jha AK, Malekzadeh K, Askari M, Mohammadi S, Marwaha RK, Kaur J. Aberrant promoter hypermethylation of selected apoptotic genes in childhood acute lymphoblastic leukemia among North Indian population. Exp Oncol 2017.
[24] Jha AK, Sharma V, Nikbakht M, et al. A comparative analysis of methylation status of tumor suppressor genes in paired biopsy and serum samples from cervical cancer patients among north Indian population. Russ J Genet 2016; 52: 226–230.
[25] Goel H, Mathur R, Syeda S, Shrivastava A, Jha AK. Promoter Hypermethylation of LATS1 Gene in Oral Squamous Cell Carcinoma (OSCC) among North Indian Population. Asian Pac J Cancer Prev 2021; 22(3): 977–982. doi: 10.31557/APJCP.2021.22.3.977. PMID: 33773564; PMCID: PMC8286665.
[26] Toperoff G, Aran D, Kark JD, Rosenberg M, Dubnikov T, Nissan B, Wainstein J, Friedlander Y, Levy-Lahad E, Glaser B, Hellman A. Genome-wide survey reveals predisposing diabetes type 2-related DNA methylation variations in human peripheral blood. Hum Mol Genet 2012; 21(2): 371–383. doi: 10.1093/hmg/ddr472. PMID: 21994764; PMCID: PMC3276288.
[27] Dor Y, Cedar H. Principles of DNA methylation and their implications for biology and medicine. Lancet 2018; 392(10149): 777–786.

[28] Willmer T, Johnson R, Pheiffer C. Blood-based DNA methylation biomarkers for type 2 diabetes: potential for clinical applications. Front Endocrinol 2018; 9: 428365.
[29] Sibuh BZ, Quazi S, Panday H, Parashar R, Jha NK, Mathur R, Jha SK, Taneja P, Jha AK. The Emerging Role of Epigenetics in Metabolism and Endocrinology. Biology 2023; 12(2): 256.
[30] Hall E, Nitert MD, Volkov P, Malmgren S, Mulder H, Bacos K, Ling C. The effects of high glucose exposure on global gene expression and DNA methylation in human pancreatic islets. Mol Cell Endocrinol 2018; 472: 57–67.
[31] Ahmed SAH, Ansari SA, Mensah-Brown EP, Emerald BS. The role of DNA methylation in the pathogenesis of type 2 diabetes mellitus. Clin Epigenetics 2020; 12(1): 104.
[32] Ling C, Del Guerra S, Lupi R, Rönn T, Granhall C, Luthman H, Del Prato S. Epigenetic regulation of PPARGC1A in human type 2 diabetic islets and effect on insulin secretion. Diabetologia 2008; 51: 615–622.
[33] Coellar JD, Long J, Danesh FR. Long noncoding RNAs and their therapeutic promise in diabetic nephropathy. Nephron 2021; 145(4): 404–414.
[34] Biswas S, Chakrabarti S. Increased extracellular matrix protein production in chronic diabetic complications: implications of non-coding RNAs. Non-coding RNA 2019; 5(1): 30.
[35] Sathishkumar C, Prabu P, Mohan V, Balasubramanyam M. Linking a role of lncRNAs (long non-coding RNAs) with insulin resistance, accelerated senescence, and inflammation in patients with type 2 diabetes. Hum Genomics 2018; 12: 1–9.
[36] Yadav P, Chakraborty P, Jha NK, Dewanjee S, Jha AK, Panda SP, Mishra PC, Dey A, Jha SK. Molecular Mechanism and Role of Japanese Encephalitis Virus Infection in Central Nervous System-Mediated Diseases. Viruses 2022; 14: 2686.
[37] Yang Y, Luan Y, Feng Q, Chen X, Qin B, Ren KD, Luan Y. Epigenetics and beyond: targeting histone methylation to treat type 2 diabetes mellitus. Front Pharmacol 2022; 12: 807413.
[38] Hu S, Cho EH, Lee JY. Histone deacetylase 9: its role in the pathogenesis of diabetes and other chronic diseases. Diabetes Metab J 2020; 44(2): 234–244.
[39] Lu HC, Dai WN, He LY. Epigenetic histone modifications in the pathogenesis of diabetic kidney disease. Diabetes Metab Syndr Obes 2021; 329–344.
[40] Kaimala S, Kumar CA, Allouh MZ, Ansari SA, Emerald BS. Epigenetic modifications in pancreas development, diabetes, and therapeutics. Med Res Rev 2022; 42(3): 1343–1371.
[41] Goel H, Singhal S, Mathur R, Syeda S, Gupta RK, Kumar A, Shrivastava A, Jha AK. Promoter Hypermethylation of LATS2 Gene in Oral Squamous Cell Carcinoma (OSCC) Among North Indian Population. Asian Pac J Cancer Prev 2020; 21(5): 1283–1287.